The recently created UZH Life Sciences Fund is making its first investment, putting one million CHF into CUTISS, a young company aiming to bring bioengineered skin grafts to market. The fund will be investing in further spin-offs with the goal of accelerating the transfer of UZH research findings into practice. The UZH Life Sciences Fund is financed by equal contributions from the UZH Foundation and the Novartis Venture Fund.
CUTISS is a company with a vision: To use personalized skin grafts to heal people all over the world with skin defects, including burn victims. The UZH spin-off has developed a novel procedure whereby a postage-stamp-sized biopsy of healthy skin is harvested from the patient. This is then bioengineered to create a skin graft around 70 times larger in size in around a month. The skin produced in the lab and subsequently transplanted is elastic and grows with the patient. It is expected to result in less scarring than with conventional grafts and to provide a significantly better quality of life for patients.
Taking development to market maturity
While the ground-breaking idea and its underlying innovative technology are in place and the first clinical safety trials have been successfully completed, the skin substitute – unique anywhere in the world – isn’t yet ready for market. The production process has to be automated to enable the skin grafts to be used on a broad basis. This will require further investment – which is precisely where the UZH Life Sciences Fund comes in. With an investment of one million Swiss francs, the fund is enabling CUTISS to take the next steps in moving its business forward and accelerating the development of a marketable product.
“This funding will enable us to tackle the challenge of automating the process for cultivating skin, allowing us to produce skin grafts more quickly and cost-efficiently,” explains CUTISS CEO Daniela Marino, a biologist whose research into novel skin substitutes goes back to 2009. The method for producing personalized skin transplants was developed by the Tissue Biology Research Unit of the Department of Surgery of the University Children’s Hospital in Zurich.
Accelerating the transfer of knowledge into practice
CUTISS is the first spin-off in which the UZH Life Sciences Fund has invested. Over the next six years the fund plans to provide start-up financing for further young companies, focusing on UZH spin-offs in life sciences and biotechnology with business ideas based on research done at the university. UZH supports entrepreneurial researchers within its ranks who are launching start-ups. The aim is to accelerate the development process of spin-offs, which have a particularly hard time raising funds in the early phase of their life cycle.
“It takes a long time to develop marketable applications, especially in the life sciences, and clinical trials are expensive,” says Michael Hengartner, UZH president and a member of the UZH Life Sciences Fund board. “The UZH Life Sciences Fund accelerates the transfer of research findings from UZH into clinical practice, which ultimately benefits patients and the public at large.”
Two equal partners with a shared goal
The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. “We share the goal of promoting innovation in the Swiss life science and biotechnology sectors,” explains Anja König, Global Head of the Novartis Venture Fund. Investment decisions are made by a committee comprising equal numbers of representatives from the UZH Foundation and the
Novartis Venture Fund.
The fund aims to amass a total of 20 million Swiss francs, with the two partner funds contributing half each. The UZH Foundation’s share of the funding will come from donations. Three million francs have been raised so far; seven million still have to be found. The Novartis Venture Fund matches the contributions raised by the UZH Foundation. Any revenues flowing back from the spin-offs remain in the UZH Life Sciences Fund for investment in further spin-offs.
Innovation at UZH
Pure research provides fertile ground for innovation. UZH is one of the most innovative universities in Europe. Many successful discoveries at UZH have been translated into new products. More than 100 spin-offs have been established at UZH since 1999. These new companies have a very high rate of survival, with more than 94% still in operation after five years. UZH also has a portfolio of more than 300 licenses in the fields of biotechnology, medical technology, information and computer technology, and multimedia.
The UZH Foundation seeks donations and bequests from private individuals, foundations, and companies to achieve its fundamental goal of promoting excellence at the University of Zurich. By giving support, donors become part of the ground-breaking work done by University of Zurich researchers. Donations to the UZH Foundation accelerate the progress made in research and education, bringing benefits to society at large.www.nvfund.com
Nathalie Huber | Universität Zürich
First transcatheter implant for diastolic heart failure successful
16.11.2017 | The Ohio State University Wexner Medical Center
Theranostic nanoparticles for tracking and monitoring disease state
13.11.2017 | SLAS (Society for Laboratory Automation and Screening)
The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.
Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...
Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.
That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...
Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.
During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....
The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.
Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...
Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
17.11.2017 | Physics and Astronomy
17.11.2017 | Health and Medicine
17.11.2017 | Studies and Analyses